BioMarin Pharmaceutical (BMRN) Competitors $62.56 +0.59 (+0.95%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends BMRN vs. MYOK, SRPT, RETA, TEVA, MRTX, ALNY, BIIB, UTHR, INCY, and NBIXShould you be buying BioMarin Pharmaceutical stock or one of its competitors? The main competitors of BioMarin Pharmaceutical include MyoKardia (MYOK), Sarepta Therapeutics (SRPT), Reata Pharmaceuticals (RETA), Teva Pharmaceutical Industries (TEVA), Mirati Therapeutics (MRTX), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), and Neurocrine Biosciences (NBIX). These companies are all part of the "medical" sector. BioMarin Pharmaceutical vs. MyoKardia Sarepta Therapeutics Reata Pharmaceuticals Teva Pharmaceutical Industries Mirati Therapeutics Alnylam Pharmaceuticals Biogen United Therapeutics Incyte Neurocrine Biosciences MyoKardia (NASDAQ:MYOK) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, community ranking, media sentiment and analyst recommendations. Do analysts recommend MYOK or BMRN? BioMarin Pharmaceutical has a consensus target price of $94.20, indicating a potential upside of 50.58%. Given BioMarin Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than MyoKardia.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MyoKardia 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00BioMarin Pharmaceutical 0 Sell rating(s) 7 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 2.74 Does the media refer more to MYOK or BMRN? In the previous week, BioMarin Pharmaceutical had 18 more articles in the media than MyoKardia. MarketBeat recorded 18 mentions for BioMarin Pharmaceutical and 0 mentions for MyoKardia. BioMarin Pharmaceutical's average media sentiment score of 0.61 beat MyoKardia's score of 0.00 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media. Company Overall Sentiment MyoKardia Neutral BioMarin Pharmaceutical Positive Does the MarketBeat Community favor MYOK or BMRN? BioMarin Pharmaceutical received 1271 more outperform votes than MyoKardia when rated by MarketBeat users. Likewise, 74.52% of users gave BioMarin Pharmaceutical an outperform vote while only 67.90% of users gave MyoKardia an outperform vote. CompanyUnderperformOutperformMyoKardiaOutperform Votes29467.90% Underperform Votes13932.10% BioMarin PharmaceuticalOutperform Votes156574.52% Underperform Votes53525.48% Is MYOK or BMRN more profitable? BioMarin Pharmaceutical has a net margin of 11.71% compared to MyoKardia's net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 8.53% beat MyoKardia's return on equity.Company Net Margins Return on Equity Return on Assets MyoKardiaN/A -47.99% -42.42% BioMarin Pharmaceutical 11.71%8.53%6.40% Do institutionals and insiders believe in MYOK or BMRN? 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 4.3% of MyoKardia shares are owned by company insiders. Comparatively, 1.9% of BioMarin Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has better earnings & valuation, MYOK or BMRN? BioMarin Pharmaceutical has higher revenue and earnings than MyoKardia. MyoKardia is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMyoKardia$33.56M357.36-$276.21M-$4.38-51.35BioMarin Pharmaceutical$2.42B4.93$167.65M$1.6737.46 Which has more risk & volatility, MYOK or BMRN? MyoKardia has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. SummaryBioMarin Pharmaceutical beats MyoKardia on 16 of the 19 factors compared between the two stocks. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get BioMarin Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMRN vs. The Competition Export to ExcelMetricBioMarin PharmaceuticalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.92B$6.43B$5.04B$8.82BDividend YieldN/A8.11%5.17%4.07%P/E Ratio37.4610.10122.4217.58Price / Sales4.93243.351,179.2973.96Price / Cash35.4522.1633.5632.51Price / Book2.385.474.694.68Net Income$167.65M$153.61M$118.98M$225.87M7 Day Performance-6.15%-4.33%-2.45%-2.03%1 Month Performance-10.77%-8.62%-4.03%0.07%1 Year Performance-28.53%28.78%29.80%24.55% BioMarin Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMRNBioMarin Pharmaceutical4.9885 of 5 stars$62.56+1.0%$94.20+50.6%-28.5%$11.92B$2.42B37.463,401MYOKMyoKardiaN/A$224.91flatN/AN/A$11.99B$33.56M-51.35318News CoverageSRPTSarepta Therapeutics4.9373 of 5 stars$110.86+4.0%$181.33+63.6%+33.5%$10.18B$1.64B88.691,314Analyst DowngradeGap UpRETAReata PharmaceuticalsN/A$172.36+0.0%N/A+0.0%$6.58B$23.48M0.00321Analyst ForecastTEVATeva Pharmaceutical Industries2.6924 of 5 stars$17.03+1.2%$19.67+15.5%+80.0%$19.04B$15.85B0.0037,851MRTXMirati Therapeutics0.5659 of 5 stars$58.70flat$59.00+0.5%N/A$4.12B$12.44M-4.80587Analyst ForecastALNYAlnylam Pharmaceuticals4.3868 of 5 stars$248.79+6.2%$298.09+19.8%+50.5%$32.09B$1.83B-94.962,100Analyst ForecastBIIBBiogen4.8601 of 5 stars$156.00+0.4%$258.96+66.0%-32.2%$22.73B$9.84B14.097,570Analyst DowngradeUTHRUnited Therapeutics4.5219 of 5 stars$364.33+1.0%$370.86+1.8%+59.1%$16.10B$2.33B16.001,168Positive NewsINCYIncyte3.9 of 5 stars$71.05+0.7%$77.16+8.6%+29.9%$13.69B$3.70B507.542,524Analyst ForecastNBIXNeurocrine Biosciences4.9503 of 5 stars$123.29+3.5%$163.91+32.9%+12.7%$12.06B$1.89B33.051,400Positive News Related Companies and Tools Related Companies MYOK Competitors SRPT Competitors RETA Competitors TEVA Competitors MRTX Competitors ALNY Competitors BIIB Competitors UTHR Competitors INCY Competitors NBIX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BMRN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
